Research Article
BibTex RIS Cite
Year 2021, Volume: 4 Issue: 6, 835 - 839, 24.09.2021
https://doi.org/10.32322/jhsm.972723

Abstract

Supporting Institution

YOK

References

  • Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and sars-cov-2. Turk J Med Sci 2020; 50: 549-56.
  • Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55: 105924.
  • Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med 2020; 382: 1708-20.
  • Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Am J Roentgenol 2020; 215: 87-93.
  • Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis. J Med Virol 2020; 92: 1518-24.
  • Hao W, Li M. Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing. Travel Med Infect Dis 2020; 34: 101607.
  • Wang S, Kang B, Ma J, et al. A deep learning algorithm using CT images to screen for corona virus disease (COVID-19). Eur Radiol 2021: 1-9.
  • Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020; 55: 105955.
  • COVID-19 Information Page. Access date: 11, 2020. Access: https://covid19.saglik.gov.tr/TR 66935/genelkoronavirus-tablosu.html
  • British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection. Guidance for the reporting radiologist. Version 2. 16 March 2020 [Internet]. UK BSTI [Access 15 June 2020].https:\\www.bsti.org.uk\media\resources\files\BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20.pdf.
  • Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy 2020; 75: 1730-41.
  • World Health Organization. (2020). Coronavirus disease 2019 (COVID-19): situation report, 60. https://www.who.int/health-topics/coronavirus#tab=- tab_3. Access date 01.07.2020.
  • Karakoc ZC, Pinarbasi Simsek B, Asil R, et al. First wave in the COVID-19 pandemic: one center experience. Klimik J/Klimik Derg 202; 33: 3.
  • Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 395: 1054-62.
  • Elshafeey F, Magdi R, Hindi N, et al. A systematic scoping review of COVID‐19 during pregnancy and childbirth. Int J Gynecol Obstet 2020; 150: 47-52.
  • Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama 2020; 323: 1061-9.
  • Turkey Health Ministry (2020). General Directorate of Public Health, Covid-19 (SARS-CoV-2) guide (Scientific Committee Study). Access date:10 July 2020. Available from: https:\\hsgm.saglik.gov.tr\tr\covid19.
  • Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama 2020; 323: 1239-42.
  • Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med 2006; 23: 623-8.
  • Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care 2010; 33: 1491-3.
  • Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. Jama 2020; 323: 1545-6.
  • Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71.
  • Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir Res 2018; 153: 85-94.
  • Turkey Health Ministry (2020). The current situation in Turkey. 2020. Available from https:\\saglik.gov.tr\Access date: June 1, 2020.
  • World Health Organization. (2020). WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020.
  • Eraksoy, H. COVID-19 Pandemic: Leaving First Four Months Behind/ COVID-19 Pandemic. KLIMIK J 2020; 33: 1-2.
  • Genç A, Kurtaiş Aytür Y. Acute and Post-acute pulmonary rehabilitation in COVID-19 infection. COVID-19 Pandemisi ve Fiziksel Tıp ve Rehabilitasyon. 1st Edition. Ankara: Türkiye Klinikleri; 2020; 7-12.

Clinical and prognostic evaluation of patients admitted to the COVID-19 pandemic unit of the emergency department

Year 2021, Volume: 4 Issue: 6, 835 - 839, 24.09.2021
https://doi.org/10.32322/jhsm.972723

Abstract

Objective: This study aimed to evaluate to prognosis of patients admitted to the COVID-19 isolation unit of the emergency department and present epidemiological data by examining their demographic, clinical, laboratory and lung tomography findings.
Material and Method: A total of 504 patients presenting with COVID-19 symptoms were randomly and retrospectively evaluated based on electronic records obtained from the hospital archive.
Results: Of the patients, 216 (42.9%) were female and 288 (57%) were male. The RT-PCR test was positive in 291 (57.7%) patients, and fever was the most common symptom in 280 (55.5%). A total of 133 patients (26.4%) were admitted to the inpatient ward. The WBC, Troponin-t, CRP, AST, ALT, LDH, D-dimer and ferritin levels were high and lymphocyte count was low in patients who were hospitalized. Sixty-one percent of the patients had a comorbid condition; 19% of had diabetes and 18.8% had hypertension as the most common underlying condition. Totally, 312 (61.9%) had favipiravir, 106 (21%) were favipiravir + hydroxychloroquine, 60 (11.9%) used hydroxychloroquine alone, 26 (5.2%) were followed up without treatment and to 147 of them, antibiotics were prescribed in addition to the medicine; 38.5% of the patients followed up in the intensive care unit were diabetic; 26 patients (5.2%) were followed up in the intensive care unit. The mortality rate was found to be 1.9%. At least one comorbid condition was present in all who were hospitalized and died in the intensive care unit.
Conclusion: The importance of a healthy diet and regular physical activity for metabolic conditions such as diabetes and hypertension as well as for fighting infections is well known. We consider that the mortality and morbidity rates due to the COVID-19 pandemic can be reduced by developing reliable and safe antiviral treatment options and implementing effective and fair vaccination policies.

References

  • Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and sars-cov-2. Turk J Med Sci 2020; 50: 549-56.
  • Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55: 105924.
  • Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med 2020; 382: 1708-20.
  • Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Am J Roentgenol 2020; 215: 87-93.
  • Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis. J Med Virol 2020; 92: 1518-24.
  • Hao W, Li M. Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing. Travel Med Infect Dis 2020; 34: 101607.
  • Wang S, Kang B, Ma J, et al. A deep learning algorithm using CT images to screen for corona virus disease (COVID-19). Eur Radiol 2021: 1-9.
  • Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020; 55: 105955.
  • COVID-19 Information Page. Access date: 11, 2020. Access: https://covid19.saglik.gov.tr/TR 66935/genelkoronavirus-tablosu.html
  • British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection. Guidance for the reporting radiologist. Version 2. 16 March 2020 [Internet]. UK BSTI [Access 15 June 2020].https:\\www.bsti.org.uk\media\resources\files\BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20.pdf.
  • Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy 2020; 75: 1730-41.
  • World Health Organization. (2020). Coronavirus disease 2019 (COVID-19): situation report, 60. https://www.who.int/health-topics/coronavirus#tab=- tab_3. Access date 01.07.2020.
  • Karakoc ZC, Pinarbasi Simsek B, Asil R, et al. First wave in the COVID-19 pandemic: one center experience. Klimik J/Klimik Derg 202; 33: 3.
  • Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 395: 1054-62.
  • Elshafeey F, Magdi R, Hindi N, et al. A systematic scoping review of COVID‐19 during pregnancy and childbirth. Int J Gynecol Obstet 2020; 150: 47-52.
  • Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama 2020; 323: 1061-9.
  • Turkey Health Ministry (2020). General Directorate of Public Health, Covid-19 (SARS-CoV-2) guide (Scientific Committee Study). Access date:10 July 2020. Available from: https:\\hsgm.saglik.gov.tr\tr\covid19.
  • Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama 2020; 323: 1239-42.
  • Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med 2006; 23: 623-8.
  • Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care 2010; 33: 1491-3.
  • Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. Jama 2020; 323: 1545-6.
  • Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71.
  • Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir Res 2018; 153: 85-94.
  • Turkey Health Ministry (2020). The current situation in Turkey. 2020. Available from https:\\saglik.gov.tr\Access date: June 1, 2020.
  • World Health Organization. (2020). WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020.
  • Eraksoy, H. COVID-19 Pandemic: Leaving First Four Months Behind/ COVID-19 Pandemic. KLIMIK J 2020; 33: 1-2.
  • Genç A, Kurtaiş Aytür Y. Acute and Post-acute pulmonary rehabilitation in COVID-19 infection. COVID-19 Pandemisi ve Fiziksel Tıp ve Rehabilitasyon. 1st Edition. Ankara: Türkiye Klinikleri; 2020; 7-12.
There are 27 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Original Article
Authors

Şenay Öztürk Durmaz 0000-0002-5260-2682

Ayşenur Sümer Coşkun 0000-0001-9791-1510

Ata Nevzat Yalçın 0000-0002-7243-7354

Publication Date September 24, 2021
Published in Issue Year 2021 Volume: 4 Issue: 6

Cite

AMA Öztürk Durmaz Ş, Sümer Coşkun A, Yalçın AN. Clinical and prognostic evaluation of patients admitted to the COVID-19 pandemic unit of the emergency department. J Health Sci Med / JHSM. September 2021;4(6):835-839. doi:10.32322/jhsm.972723

Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].

The Directories (indexes) and Platforms we are included in are at the bottom of the page.

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show







The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.

       images?q=tbn:ANd9GcRB9r6zRLDl0Pz7om2DQkiTQXqDtuq64Eb1Qg&usqp=CAU

500px-WorldCat_logo.svg.png

atifdizini.png

logo_world_of_journals_no_margin.png

images?q=tbn%3AANd9GcTNpvUjQ4Ffc6uQBqMQrqYMR53c7bRqD9rohCINkko0Y1a_hPSn&usqp=CAU

doaj.png  

images?q=tbn:ANd9GcSpOQFsFv3RdX0lIQJC3SwkFIA-CceHin_ujli_JrqBy3A32A_Tx_oMoIZn96EcrpLwTQg&usqp=CAU

ici2.png

asos-index.png

drji.png





The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.

COPE-logo-300x199.jpgimages?q=tbn:ANd9GcQR6_qdgvxMP9owgnYzJ1M6CS_XzR_d7orTjA&usqp=CAU

icmje_1_orig.png

cc.logo.large.png

ncbi.pngimages?q=tbn:ANd9GcRBcJw8ia8S9TI4Fun5vj3HPzEcEKIvF_jtnw&usqp=CAU

ORCID_logo.png

1*mvsP194Golg0Dmo2rjJ-oQ.jpeg


Our Journal using the DergiPark system indexed are;

Ulakbim TR Dizin,  Index Copernicus, ICI World of JournalsDirectory of Research Journals Indexing (DRJI), General Impact FactorASOS Index, OpenAIRE, MIAR,  EuroPub, WorldCat (OCLC)DOAJ,  Türkiye Citation Index, Türk Medline Index, InfoBase Index


Our Journal using the DergiPark system platforms are;

Google, Google Scholar, CrossRef (DOI), ResearchBib, ICJME, COPE, NCBI, ORCID, Creative Commons, Open Access, and etc.


Journal articles are evaluated as "Double-Blind Peer Review". 

Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user.  https//dergipark.org.tr/tr/pub/jhsm/page/9535

Journal charge policy   https://dergipark.org.tr/tr/pub/jhsm/page/10912


Editor List for 2022

Assoc. Prof. Alpaslan TANOĞLU (MD)  

Prof. Aydın ÇİFCİ (MD)

Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)

Prof. Murat KEKİLLİ (MD)

Prof. Yavuz BEYAZIT (MD) 

Prof. Ekrem ÜNAL (MD)

Prof. Ahmet EKEN (MD)

Assoc. Prof. Ercan YUVANÇ (MD)

Assoc. Prof. Bekir UÇAN (MD) 

Assoc. Prof. Mehmet Sinan DAL (MD)


Our journal has been indexed in DOAJ as of May 18, 2020.

Our journal has been indexed in TR-Dizin as of March 12, 2021.


17873

Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.